The Urticaria Voices Study: Physicians’ Perspectives on the Real-World Patient Burden, Treatments, and Outcomes in Chronic Spontaneous Urticaria
Improving patients' QOL and diagnosis- and treatment-related challenges is critical in CSU management from physicians' perspective. Despite higher satisfaction with omalizumab, predominant use of sgH1-AH and reluctance to escalate to omalizumab indicate areas for improving treatment strategies in CSU care. Notably, reluctance to escalate to biologics may be partly due to limited availability and barriers to access in certain countries, which must be addressed to optimize care globally.
Authors
- Pallavi Prakash Saraswat (ORCID: https://orcid.org/0000-0002-4374-9543)
- Nadine Chapman‐Rothe
- Tonya Winders (ORCID: https://orcid.org/0000-0001-7689-6438)
- Jessica McCarthy (ORCID: https://orcid.org/0000-0002-5771-2274)
- Karsten Weller (ORCID: https://orcid.org/0000-0003-4437-0313)
- Tara C. Raftery
- Jonathan A. Bernstein (ORCID: https://orcid.org/0000-0001-5369-346X)
Institutions
- Novartis (Switzerland) (CH)
- Humboldt-Universität zu Berlin (DE)
- Novartis (India) (IN)
- Bernstein Clinical Research Center (US)
- Novartis (United States) (US)
- Novartis (Ireland) (IE)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1007/s13555-025-01498-9
- Citations
- 1
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 1.67
Funders
- Asthma and Allergy Foundation of America
- Novartis Pharma